A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-11. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Charlemagne founded the Carolingian Empire in 800; it was divided in 843. The eastern successor kingdom of East Francia stretched from the Rhine in the west to the Elbe river in the east and from the North Sea to the Alps. Subsequently, the Kingdom of Germany and the Holy Roman Empire emerged from it. The Ottonian rulers (919–1024) consolidated several major duchies. In 996, Gregory V became the first German Pope, appointed by his cousin Otto III, whom he shortly after crowned Holy Roman Emperor. The Holy Roman Empire absorbed northern Italy and Burgundy under the Salian emperors (1024–1125), although the emperors lost power through the Investiture Controversy. Under the Hohenstaufen emperors (1138–1254), German princes encouraged German settlement to the south and east (Ostsiedlung). Members of the Hanseatic League, mostly north German towns, prospered in the expansion of trade. The population declined starting with the Great Famine in 1315, followed by the Black Death of 1348–1350. The Golden Bull issued in 1356 provided the constitutional structure of the Empire and codified the election of the emperor by seven prince-electors. Johannes Gutenberg introduced moveable-type printing to Europe, laying the basis for the democratisation of knowledge. Following Martin Luther's 1517 Protestant Reformation, bolstered by his standardised Bible translation, led to the 1555 Peace of Augsburg, which recognised Lutheranism under the principle of cuius regio, eius religio (ruler's faith dictates subjects' faith).
== External links == Anatomy Atlases – Microscopic Anatomy, plate 07.141 - "Axillary Sweat Gland: Myoepithelium" Histology image: 43_13 at the University of Oklahoma Health Sciences Center - "thick skin" Histology at KUMC glands-glands09 "Simple Tubular Coiled" Costoff, A., Essentials of Human Physiology, archived from the original on 2015-11-20{{citation}}: CS1 maint: bot: original URL status unknown (link)
=== Decarboxylation === Ketonic decarboxylation is a method useful for producing symmetrical ketones from carboxylic acids. The process involves reactions of the carboxylic acid with an inorganic base. Stearone is prepared by heating magnesium stearate.
=== General === A 2020 study of data from 1999 to 2015 suggests that children living with married parents tended to have lower rates of early-life mortality than those living with unmarried or single parents and non-parents.
Sources: en.wikipedia.org
== Biosynthesis == The gene cluster for viomycin has been sequenced from Streptomyces sp. strain ATCC 11861, Streptomyces vinaceus and from Streptomyces lividans 1326. It consists of a central cyclic pentapeptide code assembled from nonribosomal peptide synthetase (NRPS). The NRPS contains 4 proteins: VioA, VioF, VioI, and VioG. These proteins condense and cyclize two molecules of L-2,3-diaminopropionate (L-Dap), two molecules of L-serine (L-Ser), and one molecule of (2S,3R)-capreomycidine (L-Cam). After cyclizing these, VioJ catalyzes the α,β-desaturation of this preliminary structure. It is proposed that the viomycin gene cluster includes 36.3 kb of contiguous DNA that encodes 20 open reading frames (ORFs) that are involved in the biosynthesis, regulation, and eventual activation viomycin. In addition to these ORFs, the structure contains the resistance gene vph. The following is a summary of the ORFs and their functions.
=== Pharmacokinetics === The drug is rapidly absorbed after oral administration and is widely distributed throughout the body. Biotransformation is low: the drug is predominantly excreted unchanged by the kidneys. The serum half-life of baclofen is roughly 2–4 hours; however, one source gives a half-life of 6.8 hours, using a more complex calculation combining urinary and serum data. It therefore needs to be administered frequently throughout the day to control spasticity appropriately.
Brazil occupies nearly half of the land area of South America (47.7%), including a large area along its eastern coast and much of the continent's interior. It borders Uruguay to the south; Argentina and Paraguay to the southwest; Bolivia and Peru to the west; Colombia to the northwest; and Venezuela, Guyana, Suriname, and France (French overseas region of French Guiana) to the north. It shares a border with every South American country except Ecuador and Chile. The Brazilian territory also encompasses a number of oceanic archipelagos, such as Fernando de Noronha, Rocas Atoll, Saint Peter and Saint Paul Archipelago, and the islands of Trindade and Martim Vaz. Its size, relief, climate, and natural resources make Brazil geographically diverse. Including its Atlantic islands, Brazil lies between latitudes 6°N and 34°S, and longitudes 28° and 74°W. Brazil is the fifth largest country in the world, and third largest in the Americas, with a total area of 8,515,767.049 km2 (3,287,956 sq mi), including 55,455 km2 (21,411 sq mi) of water. Brazil is the only country in the world that has the equator and the Tropic of Capricorn running through it. It spans four time zones; from UTC−5 comprising the state of Acre and the westernmost portion of Amazonas, to UTC−4 in the western states, to UTC−3 in the eastern states (the national time) and UTC−2 in the Atlantic islands.
While it is true that increased pressure, such as that exerted by someone standing on a sheet of ice, will lower the melting point of ice, experiments show that the effect is too weak to account for the lowered friction. Materials scientists still debate whether premelting or the heat of friction is the dominant cause of ice's slipperiness.
==== Hardware wallets ==== A hardware "wallet" is a small and portable computer peripheral that signs transactions as requested by the user. These devices store private keys and carry out signing and encryption internally, and do not share any sensitive information with the host computer except already signed (and thus unalterable) transactions. Because hardware wallets never expose their private keys, even computers that may be compromised by malware do not have a vector to access or steal them.The user sets a passcode when setting up a hardware signer. As hardware signers are tamper-resistant, without the passcode the assets cannot be accessed.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.